Stanley Druckenmiller and 25 Other Big Funds Sold Thermo Fisher Scientific Last Quarter, While 15 Bought. Who’s Right?

26 large funds, including Stanley Druckenmiller's Duquesne, sold Thermo Fisher Scientific (TMO) last quarter, while 15 bought. Viking Global sold $687M, Lone Pine bought $673M. Thermo Fisher raised 2026 outlook, and Danaher's guidance suggests improving demand. Analysts' average price target is achievable through earnings growth alone. Danaher (DHR) serves similar customers, potentially indicating market trends.

Original reporting
Published Nov 22, 2026, 10:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 22, 2026, 10:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Stanley Druckenmiller and 25 Other Big Funds Sold Thermo Fisher Scientific Last Quarter, While 15 Bought. Who’s Right? — source image
Decision brief

The 30-second read

$TMONeutralMed
01

Why it matters

Fund activity of this magnitude can influence short‑term price dynamics and inform traders about institutional sentiment.

02

Market read

Large fund moves in a mega‑cap biotech equipment company provide actionable insight for short‑term traders.

03

What to watch

Thermo Fisher's recent 2026 outlook raise and Danaher’s guidance may offset fund sell signals.

Relevance 7/10Novelty 7/10Timing: post‑quarter filing release

Background

The article summarizes 13F filings for the quarter ended Sept. 30, 2026, highlighting fund turnover in Thermo Fisher Scientific (TMO).

Company-level read

Ticker impact

$TMONeutralHigh confidence
Context

13F filings show several large funds sold Thermo Fisher while others bought, indicating mixed sentiment and potential near‑term volatility.

Expected impact

potential volatility with pressure from sellers and support from buyers; direction unclear

Evidence & confidence

The article provides the first public disclosure of sizable fund trades ($687M sold, $673M bought) that can move the stock.

Market effects

Thermo Fisher's biotech and lab‑equipment sector may see heightened attention as fund flows signal valuation debate.

U.S. investors may adjust exposure to the broader life‑sciences space.

Limited to investors tracking large‑cap biotech equipment stocks.

Counterpoint

The sizable buy side (Lone Pine, Castle Hook) could indicate undervaluation despite recent sell pressure.

Key entities

  • Thermo Fisher Scientific

    Life‑sciences equipment maker (ticker TMO).

Related articles

$TMOMed

Thermo Fisher Scientific Replenishes Buyback Capacity to $5 Billion

Thermo Fisher Scientific (TMO) authorized up to $5B in new stock repurchases, replacing a prior authorization with $1B remaining. The company spent $4B on buybacks in 2026's first nine months, with no purchases in Q3. Operating cash flow increased to $5.867B for the period, with $4.618B in free cash flow. The new authorization complements acquisitions, dividends, and debt obligations.